| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/07/1995 | WO1995032988A1 Novel parasite protease genes and proteins |
| 12/07/1995 | WO1995032987A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION |
| 12/07/1995 | WO1995032985A1 3'-(4'-) nonradioactively tagged nucleosides and nucleotides with aminocarboxylic acid, peptide or carboxylic acid spacer |
| 12/07/1995 | WO1995032982A1 Dna encoding gls1 |
| 12/07/1995 | WO1995032740A1 Transformed human hepatoma cell line which releases insulin |
| 12/07/1995 | WO1995032738A1 Modification of clostridial toxins for use as transport proteins |
| 12/07/1995 | WO1995032735A2 Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease |
| 12/07/1995 | WO1995032734A1 New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness |
| 12/07/1995 | WO1995032730A1 A pharmaceutical preparation comprising glucagon |
| 12/07/1995 | WO1995032729A1 Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity |
| 12/07/1995 | WO1995032728A1 Inhibition of attachment of h. influenzae to human cells |
| 12/07/1995 | WO1995032727A1 Inhibition of infection of mammalian cells by respiratory syncytial virus |
| 12/07/1995 | WO1995032726A1 Cyclosporin containing composition and process for the preparation thereof |
| 12/07/1995 | WO1995032725A1 Angiotensin ii for improving fertilization |
| 12/07/1995 | WO1995032724A1 Glial mitogenic factors, their preparation and use |
| 12/07/1995 | WO1995032722A1 Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof |
| 12/07/1995 | WO1995032709A1 Activation of growth factors by matrix vesicles |
| 12/07/1995 | WO1995032708A1 Use of anti-vegf agents in the treatment of endometriosis |
| 12/07/1995 | WO1995032706A1 Virosome-mediated intracellular delivery of therapeutic agents |
| 12/07/1995 | WO1995032628A1 Oligonucleotide inhibitors of cytokine production and tumors responsive to cytokines |
| 12/07/1995 | WO1995032627A1 Use of fas ligand to suppress lymphocyte-mediated immune responses |
| 12/07/1995 | WO1995030435A3 Compositions and treatment for multiple sclerosis |
| 12/07/1995 | WO1995028907A3 Megapoietin: a novel megakaryocyte growth promoting factor |
| 12/07/1995 | WO1995025749A3 Eating suppressant peptides |
| 12/07/1995 | WO1995024485A3 Coordinate in vivo gene expression |
| 12/07/1995 | WO1995021919A3 Protein having tpo activity |
| 12/07/1995 | DE4435919C1 DNA encoding zinc finger protein |
| 12/07/1995 | DE19513784A1 Hochreines Urodilatin und Verfahren zu seiner Herstellung High purity urodilatin and process for its preparation |
| 12/07/1995 | CA2191321A1 Gene coding for modified bone morphogenic protein receptor |
| 12/07/1995 | CA2191317A1 A pharmaceutical preparation comprising glucagon |
| 12/07/1995 | CA2191306A1 Hybrid molecule of formula gm-csf-l-epo or epo-l-gm-csf for hematopoietic stimulation |
| 12/07/1995 | CA2191085A1 Glial mitogenic factors, their preparation and use |
| 12/07/1995 | CA2191071A1 Flt-4 (fms-like tyrosine kinase), flt-15, variants thereof used as growth factor inhibitors |
| 12/07/1995 | CA2191070A1 Use of anti-vegf agents in the treatment of endometriosis |
| 12/07/1995 | CA2191067A1 Dna encoding gls1 |
| 12/07/1995 | CA2190982A1 3'-(4'-) nonradioactively tagged nucleosides and nucleotides with aminocarboxylic acid, peptide or carboxylic acid spacer |
| 12/07/1995 | CA2190610A1 Inhibition of attachment of h. influenzae to human cells |
| 12/07/1995 | CA2190609A1 Inhibition of infection of mammalian cells by respiratory syncytial virus |
| 12/07/1995 | CA2190265A1 Hepatitis c virus asialoglycoproteins |
| 12/07/1995 | CA2189741A1 Novel parasite protease genes and proteins |
| 12/07/1995 | CA2188812A1 New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness |
| 12/07/1995 | CA2187731A1 Activation of growth factors by matrix vesicles |
| 12/07/1995 | CA2167936A1 Tbp2 fragments of the transferrine receptor of neisseria meningitidis |
| 12/06/1995 | EP0685493A1 Tumor suppressor fusion proteins |
| 12/06/1995 | EP0685492A2 Process for the preparation of hyperpolymers of haemoglobin with uniform molecular weight |
| 12/06/1995 | EP0685491A2 Process for producing albumin preparation |
| 12/06/1995 | EP0685490A1 Process for the purification of homogeneous platelet-derived endothelial cell growth factor from a platelet lysate |
| 12/06/1995 | EP0685489A2 Tripeptide antithrombotic agents |
| 12/06/1995 | EP0684997A1 Anthrax toxin fusion proteins and uses thereof |
| 12/06/1995 | EP0684994A1 A novel family of anti-carcinoembryonic antigen chimeric antibodies |
| 12/06/1995 | EP0684990A1 Novel receptor-type phosphotyrosine phosphatase-gamma |
| 12/06/1995 | EP0684989A1 Novel receptor-type phosphotyrosine phosphatase-beta |
| 12/06/1995 | EP0684944A1 Coupling product obtained from hystamine and an amino acid |
| 12/06/1995 | EP0684842A1 Composition for use in the treatment of tumours and the immunization of humans and animals |
| 12/06/1995 | EP0684841A1 Protein conjugates, compositions containing them and their applications as medicament |
| 12/06/1995 | EP0684837A1 Methods for modifying the t cell repertoire of the immune system |
| 12/06/1995 | EP0684836A1 Combinations of retroviral inhibitors |
| 12/06/1995 | EP0684835A1 Ligand antagonists for treatment of breast cancer |
| 12/06/1995 | EP0684834A1 Microemulsions comprising therapeutic peptides |
| 12/06/1995 | EP0684833A1 Microemulsions comprising therapeutic peptides |
| 12/06/1995 | EP0684832A1 Microemulsions containing pharmaceutical compositions |
| 12/06/1995 | EP0684830A1 Inhibitors of thrombosis |
| 12/06/1995 | EP0684829A1 Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof |
| 12/06/1995 | EP0684828A1 EXPANSION OF STEM CELLS IN LONG TERM BONE MARROW CULTURES BY NEUTRALIZATION OF TGF-$g(b) |
| 12/06/1995 | EP0684823A1 Fibrinogen receptor antagonists |
| 12/06/1995 | EP0684820A1 Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
| 12/06/1995 | EP0684763A1 Method and apparatus for treating a body fluid |
| 12/06/1995 | EP0647131B1 Dermatological agent for aiding oxygen transport in the skin |
| 12/06/1995 | EP0647129B1 Topical application composition |
| 12/06/1995 | EP0529076B1 Proteins with fibroblast growth factor receptor activity |
| 12/06/1995 | EP0520021B1 Pharmaceutical compositions |
| 12/06/1995 | EP0500847B1 Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
| 12/06/1995 | EP0490998B1 Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| 12/06/1995 | EP0484340B1 Treatment to reduce edema for brain and musculature injuries |
| 12/06/1995 | EP0445255B1 Treatment of conditions and disease |
| 12/06/1995 | EP0429542B1 Leukocyte adhesion inhibitor |
| 12/06/1995 | EP0409962B1 Agent for inhibiting hiv-proteases |
| 12/06/1995 | CN1112933A Antigen-specific, activated T lymphocytes, detection and use |
| 12/06/1995 | CN1112932A Lactic-acid-containing cyclic depsipeptides having 18 ring atoms as endoparasiticidal agents, and pral agentr their preparation |
| 12/06/1995 | CN1112931A Schistosome vaccine peptide No.3 |
| 12/06/1995 | CN1112930A Schistosome vaccine peptide No.2 |
| 12/06/1995 | CN1112929A Schistosome vaccine peptide No.1 |
| 12/05/1995 | USRE35112 Administering phenyl butyl nitrone or derivative in carrier in dosage to prevent or reverse oxidative central nervous system tissue damage |
| 12/05/1995 | USH1509 Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate |
| 12/05/1995 | US5473056 For study of cell cycle regulation and of Rb tumor suppressor protein and of viral oncogenes |
| 12/05/1995 | US5473055 Antitumor agents; better water solubility, side effect reduction |
| 12/05/1995 | US5473054 IGF-1 analogs |
| 12/05/1995 | US5473051 Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs |
| 12/05/1995 | US5473049 Process for obtaining proinsulin possessing correctly linked cystine bridges |
| 12/05/1995 | US5473039 Inhibit lymphocyte proliferation |
| 12/05/1995 | US5472978 Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
| 12/05/1995 | US5472959 Hypotensive agents, congestive heart failure |
| 12/05/1995 | US5472945 Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| 12/05/1995 | US5472944 Suppression of megakaryocytopoiesis by neutrophil activating peptide-2 |
| 12/05/1995 | US5472943 Co-administering agonist and antagonist |
| 12/05/1995 | US5472942 Anti-thrombins |
| 12/05/1995 | US5472939 Method of treating complement mediated disorders |
| 12/05/1995 | US5472938 Pharmaceutical depot compositions containing hirudin |
| 12/05/1995 | US5472857 DNA encoding canine granulocyte colony stimulating factor (G-CSF) |
| 12/05/1995 | US5472856 Recombinant human thymopoietin proteins and uses therefor |